The Geopolitics of Vaccines: Why Health Sovereignty is the New Priority

The COVID-19 pandemic revealed a fundamental paradox: while the world's scientific community demonstrated unprecedented collaboration in vaccine development, political realities quickly reasserted themselves when supplies became scarce. The UK's success in bringing the Oxford-AstraZeneca vaccine to market in under a year showcased what rapid, coordinated effort could achieve. Yet this triumph masked deeper vulnerabilities. During the acute pandemic phase, vaccine nationalism meant that contracts and markets alone could not guarantee supply when countries prioritized their own populations.

Today, the conditions that enabled rapid global vaccine access during COVID-19 no longer hold. The international landscape has transformed dramatically. Conflict, tariffs, and growing recidivism among multilateral institutions are constraining the free flow of information, goods, and expertise necessary for effective vaccine production. Countries that were once reliable partners cannot always be counted upon to act as such in future crises. For policymakers and health officials, this new reality demands a fundamental rethinking of pandemic preparedness.

Vaccine sovereignty represents a critical shift in how nations conceptualize health security. It is not about isolation or self-sufficiency, but about strategic resilience—the ability to act quickly and independently during a crisis while remaining a reliable partner to trusted allies. This expanded understanding of national security reflects a broader recognition that the timely availability of vaccines determines not only public health outcomes but also how quickly a country can reopen its economy, protect its healthcare system, and preserve social stability.

The stakes are concrete and measurable. Analysis shows that under a worst-case scenario combining government disinvestment in vaccine preparedness and heightened protectionism from trade partners, a COVID-like pandemic ten years from now could result in 12 percent more cases, 18 percent more hospital admissions, and 28 percent more deaths compared to 2020 levels. These numbers underscore why vaccine manufacturing must be treated as core national-security infrastructure—a pillar of defense that saves lives, protects economies, and safeguards national autonomy.

In an era of strategic competition, access to vaccines increasingly depends on geopolitical positioning rather than need or equity. Countries are no longer assumed to have first access to vaccines based on regulatory speed or proximity to manufacturer headquarters. Instead, which nations receive supply first is determined by where clinical trials are conducted, where data are generated, and where manufacturing is scaled. If a country is not central to these processes, it risks becoming a secondary market in a future pandemic, even with swift domestic regulatory approval.

This reality has profound implications for global health equity. During the acute pandemic phase, the COVAX initiative emerged as a mechanism to promote equitable vaccine access, eventually delivering nearly 2 billion doses to 146 countries and averting an estimated 2.7 million deaths in lower-income settings. Yet COVAX's success cannot be replicated in an environment of heightened protectionism and competing national interests. The lesson is clear: countries that fail to develop domestic or regional vaccine capabilities will find themselves at the back of the queue when the next crisis hits.

Latin America offers instructive examples of what vaccine sovereignty can look like in practice. Cuba developed three COVID-19 vaccines independently, while Argentina created ARVAC, a recombinant protein subunit vaccine developed entirely within the country through a consortium of national research institutions. Colombia is building the VaxThera vaccine plant near Medellín, an integrated bioprocessing complex with projected capacity to produce up to 100 million doses annually and support multiple vaccine platforms including viral vectors, mRNA, and recombinant proteins.

These initiatives reveal an important truth: the challenge of vaccine sovereignty is not scientific talent, which is abundant in these regions, but rather sustained investment in industrial infrastructure and innovation ecosystems. Brazil, through Instituto Butantan and Fiocruz, has demonstrated longstanding commitment to vaccine production. The broader lesson for nations worldwide is that vaccine and health sovereignty are not luxuries but essential resilience strategies that protect against external discontinuities driven by regulatory shifts, market dynamics, or geopolitical constraints.

Governments facing geopolitical uncertainty must treat vaccine preparedness as a core priority requiring sustained investment. This requires a hybrid approach: marshalling existing domestic capabilities into a coherent sovereign manufacturing core, building surge capacity through international partnerships with trusted allies, and targeting investment to remove critical bottlenecks across the vaccine pipeline. The UK's strategy exemplifies this balanced approach—leveraging its world-class research capabilities while maintaining collaborative relationships with international partners.

As the world enters a more volatile and insecure era, resilience is no longer optional. Countries that prepare now—investing in manufacturing infrastructure, building trusted international alliances, and maintaining genomic surveillance capabilities—will protect their populations, their economies, and their sovereignty when the next pandemic strikes. For nations that delay, the choice facing their leaders will be starkly different: adapting to a position of dependency rather than agency, accepting higher mortality and economic costs, and watching as better-prepared nations secure supply first. The time to act is now.